CD19 and Buschke-Ollendorff syndrome: Given that BOS is explicitly characterized by disturbance of B cell homeostasis with increased CD19+CD21- B cells and excess of B cell activation factor (BAFF) [38], abatacept might target Tfh cells in this context, which would at least partially explain the particular improvement of patients with BOS in our study.